Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.14365/5413
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ayna, Duran, G. | - |
dc.date.accessioned | 2024-07-21T18:43:41Z | - |
dc.date.available | 2024-07-21T18:43:41Z | - |
dc.date.issued | 2024 | - |
dc.identifier.issn | 1309-4483 | - |
dc.identifier.uri | https://doi.org/10.52142/omujecm.41.2.23 | - |
dc.identifier.uri | https://hdl.handle.net/20.500.14365/5413 | - |
dc.description.abstract | Easy-to-apply liquid biopsy technique and detection of differentially expressed miRNA/lncRNAs (DEGs) may be more beneficial in multiple myeloma (MM) compared to bone marrow (BM) biopsy. We compared the gene expression levels of circulating tumor cells and BM cells in MM patients and showed differentially upregulated circulating tumor cell-derived miRNAs and lncRNAs. DEGs and related biological pathways were identified by using the R-LIMMA package, ShinyGO 0.77, and LncSEA2.0 tools. Three hundred nine lncRNAs/16 miRNAs were detected as differentially upregulated in MM patients’ circulating tumour cells. Among them, miRNAs (mainly has-miR-103a) and lncRNAs (MEG3, NEAT1, PCAT1) were detected, and only a few miRNAs and lncRNAs were related to MM in a limited number of studies. Drugs that interact with these lncRNAs were also identified. The fact that miRNAs/lncRNAs related to MM are also detected in tumor circulating cells indicates that a technically easier liquid biopsy may verify and even replace BM biopsy. © 2024 Ondokuz Mayis Universitesi. All rights reserved. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Ondokuz Mayis Universitesi | en_US |
dc.relation.ispartof | Journal of Experimental and Clinical Medicine (Turkey) | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Circulating tumour cells | en_US |
dc.subject | DEGs | en_US |
dc.subject | lncRNAs | en_US |
dc.subject | miRNA | en_US |
dc.subject | multiple myeloma | en_US |
dc.subject | 17aag | en_US |
dc.subject | antineoplastic agent | en_US |
dc.subject | cisplatin | en_US |
dc.subject | crizotinib | en_US |
dc.subject | dovitinib | en_US |
dc.subject | erlotinib | en_US |
dc.subject | irinotecan | en_US |
dc.subject | l 685458 | en_US |
dc.subject | lapatinib | en_US |
dc.subject | long untranslated RNA | en_US |
dc.subject | maternally expressed gene 3 | en_US |
dc.subject | microRNA | en_US |
dc.subject | microRNA 103a | en_US |
dc.subject | microRNA 1180 | en_US |
dc.subject | microRNA 133a 1 | en_US |
dc.subject | microRNA 15a | en_US |
dc.subject | microRNA 210 | en_US |
dc.subject | microRNA 3618 | en_US |
dc.subject | microRNA 372 | en_US |
dc.subject | microRNA 429 | en_US |
dc.subject | microRNA 4680 | en_US |
dc.subject | microRNA 4751 | en_US |
dc.subject | microRNA 4775 | en_US |
dc.subject | microRNA 548n | en_US |
dc.subject | microRNA 6829 | en_US |
dc.subject | microRNA 6883 | en_US |
dc.subject | microRNA 934 | en_US |
dc.subject | mirdametinib | en_US |
dc.subject | nuclear paraspeckle assembly transcript 1 | en_US |
dc.subject | paclitaxel | en_US |
dc.subject | palbociclib | en_US |
dc.subject | panobinostat | en_US |
dc.subject | prostate cancer associated transcript 1 | en_US |
dc.subject | rebemadlin | en_US |
dc.subject | RNA | en_US |
dc.subject | saracatinib | en_US |
dc.subject | selumetinib | en_US |
dc.subject | sorafenib | en_US |
dc.subject | tanespimycin | en_US |
dc.subject | topotecan | en_US |
dc.subject | tumor marker | en_US |
dc.subject | unclassified drug | en_US |
dc.subject | Article | en_US |
dc.subject | bone marrow biopsy | en_US |
dc.subject | circulating tumor cell | en_US |
dc.subject | controlled study | en_US |
dc.subject | differential gene expression | en_US |
dc.subject | gene expression level | en_US |
dc.subject | human | en_US |
dc.subject | major clinical study | en_US |
dc.subject | multiple myeloma | en_US |
dc.subject | protein targeting | en_US |
dc.subject | upregulation | en_US |
dc.title | Circulating tumour cells differentially express upregulated cancer biomarkers “lncRNAs and miRNAs” compared to bone marrow biopsy samples in multiple myeloma patients | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.52142/omujecm.41.2.23 | - |
dc.identifier.scopus | 2-s2.0-85197659272 | en_US |
dc.department | İzmir Ekonomi Üniversitesi | en_US |
dc.authorscopusid | 37010637600 | - |
dc.identifier.volume | 41 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.startpage | 351 | en_US |
dc.identifier.endpage | 360 | en_US |
dc.institutionauthor | Ayna, Duran, G. | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.scopusquality | Q4 | - |
dc.identifier.wosquality | N/A | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
Appears in Collections: | Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection |
CORE Recommender
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.